Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Table 1 demonstrates Aldeyra Therapeutics Inc. and Madrigal Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has Aldeyra Therapeutics Inc. and Madrigal Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Risk and Volatility

Aldeyra Therapeutics Inc. has a beta of 0.79 and its 21.00% less volatile than Standard and Poor’s 500. Competitively, Madrigal Pharmaceuticals Inc.’s 23.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.23 beta.

Liquidity

The Current Ratio of Aldeyra Therapeutics Inc. is 4.8 while its Quick Ratio stands at 4.8. The Current Ratio of rival Madrigal Pharmaceuticals Inc. is 57.5 and its Quick Ratio is has 57.5. Madrigal Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Aldeyra Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for Aldeyra Therapeutics Inc. and Madrigal Pharmaceuticals Inc.

$29 is Aldeyra Therapeutics Inc.’s average price target while its potential upside is 314.88%.

Institutional & Insider Ownership

The shares of both Aldeyra Therapeutics Inc. and Madrigal Pharmaceuticals Inc. are owned by institutional investors at 76.1% and 95.7% respectively. Aldeyra Therapeutics Inc.’s share owned by insiders are 0.94%. Comparatively, insiders own roughly 3.2% of Madrigal Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aldeyra Therapeutics Inc. has -3.61% weaker performance while Madrigal Pharmaceuticals Inc. has 23.03% stronger performance.

Summary

Madrigal Pharmaceuticals Inc. beats Aldeyra Therapeutics Inc. on 5 of the 7 factors.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.